TRAVERE THERAPEUTICS, INC. (TVTX) Operating income 2016–2025
TRAVERE THERAPEUTICS, INC. (TVTX) annual operating income history from SEC filings — each fiscal year as reported.
-$62.8MFY2025 · since FY2016: -$58.2M → -$62.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$62.8M | +80.6% |
| FY2024 | -$323.8M | +16.6% |
| FY2023 | -$388.1M | -21.4% |
| FY2022 | -$319.8M | -60.4% |
| FY2021 | -$199.4M | -13.2% |
| FY2020 | -$176.2M | -28.2% |
| FY2019 | -$137.4M | -71.6% |
| FY2018 | -$80.0M | -48.8% |
| FY2017 | -$53.8M | +7.6% |
| FY2016 | -$58.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More TVTX financial trends
TVTX RevenueTVTX Net incomeTVTX Net marginTVTX Gross profitTVTX Gross marginTVTX Operating marginTVTX Operating cash flowTVTX Free cash flowTVTX Capital expendituresTVTX Return on equityTVTX Stock buybacksTVTX Dividends paidTVTX Total assetsTVTX Total liabilitiesTVTX Shareholders’ equityTVTX overview →